JP2010539185A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010539185A5 JP2010539185A5 JP2010525061A JP2010525061A JP2010539185A5 JP 2010539185 A5 JP2010539185 A5 JP 2010539185A5 JP 2010525061 A JP2010525061 A JP 2010525061A JP 2010525061 A JP2010525061 A JP 2010525061A JP 2010539185 A5 JP2010539185 A5 JP 2010539185A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- optionally substituted
- formula
- ring
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 112
- 125000001931 aliphatic group Chemical group 0.000 claims description 42
- 229910052739 hydrogen Inorganic materials 0.000 claims description 42
- 239000001257 hydrogen Substances 0.000 claims description 42
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 39
- 125000005842 heteroatom Chemical group 0.000 claims description 32
- 229910052717 sulfur Inorganic materials 0.000 claims description 30
- 229910052757 nitrogen Inorganic materials 0.000 claims description 29
- 229910052760 oxygen Inorganic materials 0.000 claims description 28
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 22
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 20
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 20
- 125000005843 halogen group Chemical group 0.000 claims description 20
- 239000001301 oxygen Substances 0.000 claims description 20
- 239000011593 sulfur Substances 0.000 claims description 20
- 150000002431 hydrogen Chemical class 0.000 claims description 19
- 125000003118 aryl group Chemical group 0.000 claims description 18
- -1 cyano, methyl Chemical group 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims description 18
- 125000000217 alkyl group Chemical group 0.000 claims description 17
- 125000001072 heteroaryl group Chemical group 0.000 claims description 16
- 108010079245 Cystic Fibrosis Transmembrane Conductance Regulator Proteins 0.000 claims description 15
- 102000008371 intracellularly ATP-gated chloride channel activity proteins Human genes 0.000 claims description 15
- 229920006395 saturated elastomer Polymers 0.000 claims description 14
- 125000002723 alicyclic group Chemical group 0.000 claims description 12
- 125000000623 heterocyclic group Chemical group 0.000 claims description 12
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 12
- 125000001424 substituent group Chemical group 0.000 claims description 12
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 10
- 230000000694 effects Effects 0.000 claims description 10
- 125000002950 monocyclic group Chemical group 0.000 claims description 10
- 230000007812 deficiency Effects 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 125000002619 bicyclic group Chemical group 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 8
- 102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 claims description 6
- 239000012472 biological sample Substances 0.000 claims description 6
- 201000010064 diabetes insipidus Diseases 0.000 claims description 6
- 239000012634 fragment Substances 0.000 claims description 6
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 6
- 125000003107 substituted aryl group Chemical group 0.000 claims description 6
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 4
- 125000004429 atom Chemical group 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 206010003694 Atrophy Diseases 0.000 claims description 3
- 102100022548 Beta-hexosaminidase subunit alpha Human genes 0.000 claims description 3
- 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 claims description 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 3
- 206010062264 Congenital hyperthyroidism Diseases 0.000 claims description 3
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims description 3
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims description 3
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims description 3
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 3
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims description 3
- 208000017701 Endocrine disease Diseases 0.000 claims description 3
- 208000024720 Fabry Disease Diseases 0.000 claims description 3
- 201000011240 Frontotemporal dementia Diseases 0.000 claims description 3
- 206010019860 Hereditary angioedema Diseases 0.000 claims description 3
- 208000033981 Hereditary haemochromatosis Diseases 0.000 claims description 3
- 208000023105 Huntington disease Diseases 0.000 claims description 3
- 206010060378 Hyperinsulinaemia Diseases 0.000 claims description 3
- 208000000563 Hyperlipoproteinemia Type II Diseases 0.000 claims description 3
- 206010051125 Hypofibrinogenaemia Diseases 0.000 claims description 3
- 208000000038 Hypoparathyroidism Diseases 0.000 claims description 3
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 claims description 3
- 208000015439 Lysosomal storage disease Diseases 0.000 claims description 3
- 208000008955 Mucolipidoses Diseases 0.000 claims description 3
- 206010072928 Mucolipidosis type II Diseases 0.000 claims description 3
- 102100026784 Myelin proteolipid protein Human genes 0.000 claims description 3
- 206010031243 Osteogenesis imperfecta Diseases 0.000 claims description 3
- 208000018737 Parkinson disease Diseases 0.000 claims description 3
- 208000017493 Pelizaeus-Merzbacher disease Diseases 0.000 claims description 3
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims description 3
- 201000005660 Protein C Deficiency Diseases 0.000 claims description 3
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 3
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 claims description 3
- 208000022292 Tay-Sachs disease Diseases 0.000 claims description 3
- 206010045261 Type IIa hyperlipidaemia Diseases 0.000 claims description 3
- 208000004622 abetalipoproteinemia Diseases 0.000 claims description 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 3
- 230000037444 atrophy Effects 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 208000030172 endocrine system disease Diseases 0.000 claims description 3
- 201000001386 familial hypercholesterolemia Diseases 0.000 claims description 3
- 208000013746 hereditary thrombophilia due to congenital protein C deficiency Diseases 0.000 claims description 3
- 230000003451 hyperinsulinaemic effect Effects 0.000 claims description 3
- 201000008980 hyperinsulinism Diseases 0.000 claims description 3
- 150000002632 lipids Chemical class 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- 208000020460 mucolipidosis II alpha/beta Diseases 0.000 claims description 3
- 208000000638 myeloperoxidase deficiency Diseases 0.000 claims description 3
- 230000004770 neurodegeneration Effects 0.000 claims description 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 3
- 108010040003 polyglutamine Proteins 0.000 claims description 3
- 229920000155 polyglutamine Polymers 0.000 claims description 3
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims description 3
- 208000002320 spinal muscular atrophy Diseases 0.000 claims description 3
- 208000011580 syndromic disease Diseases 0.000 claims description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 2
- KLIDCXVFHGNTTM-UHFFFAOYSA-N 2,6-dimethoxyphenol Chemical group COC1=CC=CC(OC)=C1O KLIDCXVFHGNTTM-UHFFFAOYSA-N 0.000 claims description 2
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 claims description 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 2
- 125000004861 4-isopropyl phenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- 102100034452 Alternative prion protein Human genes 0.000 claims description 2
- 102000014461 Ataxins Human genes 0.000 claims description 2
- 108010078286 Ataxins Proteins 0.000 claims description 2
- 206010008025 Cerebellar ataxia Diseases 0.000 claims description 2
- 208000002678 Mucopolysaccharidoses Diseases 0.000 claims description 2
- 206010068871 Myotonic dystrophy Diseases 0.000 claims description 2
- 208000012902 Nervous system disease Diseases 0.000 claims description 2
- 208000025966 Neurological disease Diseases 0.000 claims description 2
- 108091000054 Prion Proteins 0.000 claims description 2
- 208000024777 Prion disease Diseases 0.000 claims description 2
- 208000021811 Sandhoff disease Diseases 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 2
- 229960005475 antiinfective agent Drugs 0.000 claims description 2
- 239000004599 antimicrobial Substances 0.000 claims description 2
- 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 claims description 2
- 229940124630 bronchodilator Drugs 0.000 claims description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 210000003591 cerebellar nuclei Anatomy 0.000 claims description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- 230000007547 defect Effects 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 claims description 2
- 239000003172 expectorant agent Substances 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 238000001727 in vivo Methods 0.000 claims description 2
- 125000001041 indolyl group Chemical group 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 229940066491 mucolytics Drugs 0.000 claims description 2
- 206010028093 mucopolysaccharidosis Diseases 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- 235000016709 nutrition Nutrition 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 230000020978 protein processing Effects 0.000 claims description 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 2
- 125000004076 pyridyl group Chemical group 0.000 claims description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 2
- 125000006413 ring segment Chemical group 0.000 claims description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 208000006302 Laron syndrome Diseases 0.000 claims 1
- 230000005856 abnormality Effects 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 201000001036 autosomal recessive chronic granulomatous disease cytochrome b-positive type I Diseases 0.000 claims 1
- 239000000168 bronchodilator agent Substances 0.000 claims 1
- 208000002956 hereditary pulmonary emphysema Diseases 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 0 C*1CCCCC1 Chemical compound C*1CCCCC1 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 206010013883 Dwarfism Diseases 0.000 description 2
- 206010014561 Emphysema Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000001898 pallidal effect Effects 0.000 description 2
- 210000000463 red nucleus Anatomy 0.000 description 2
- 208000014644 Brain disease Diseases 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 208000024571 Pick disease Diseases 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000003274 myotonic effect Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 201000003624 spinocerebellar ataxia type 1 Diseases 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97259907P | 2007-09-14 | 2007-09-14 | |
| US60/972,599 | 2007-09-14 | ||
| PCT/US2008/076376 WO2009036412A1 (en) | 2007-09-14 | 2008-09-15 | Modulators of cystic fibrosis transmembrane conductance regulator |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010539185A JP2010539185A (ja) | 2010-12-16 |
| JP2010539185A5 true JP2010539185A5 (cg-RX-API-DMAC7.html) | 2012-10-25 |
| JP5461405B2 JP5461405B2 (ja) | 2014-04-02 |
Family
ID=39877483
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010525061A Expired - Fee Related JP5461405B2 (ja) | 2007-09-14 | 2008-09-15 | 嚢胞性線維症膜コンダクタンス制御因子の調節因子 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US8188283B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2201010B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5461405B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN101821266B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2008298545B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2699382C (cg-RX-API-DMAC7.html) |
| ES (1) | ES2445442T3 (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ583878A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2009036412A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA06002567A (es) | 2003-09-06 | 2006-09-04 | Vertex Pharma | Moduladores de transportadores con casete de union de atp. |
| CN1925854A (zh) * | 2003-11-14 | 2007-03-07 | 沃泰克斯药物股份有限公司 | 可用作atp－结合弹夹转运蛋白调控剂的噻唑和噁唑 |
| US7977322B2 (en) | 2004-08-20 | 2011-07-12 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
| ME02799B (me) * | 2004-06-24 | 2018-01-20 | Vertex Pharma | Modulatori ATP-vezujućih kasetnih transportera |
| WO2007021982A2 (en) * | 2005-08-11 | 2007-02-22 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| SI1945632T1 (sl) | 2005-11-08 | 2014-03-31 | Vertex Pharmaceuticals Incorporated | Heterocikliäśni modulatorji za prenaĺ alce z atp-vezavno kaseto |
| CA2635581C (en) | 2005-12-28 | 2017-02-28 | Vertex Pharmaceuticals Incorporated | Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| CN101395147B (zh) | 2005-12-28 | 2013-05-29 | 弗特克斯药品有限公司 | 作为atp-结合盒转运蛋白调节剂用于治疗囊性纤维化的1-(苯并[d][1,3]间二氧杂环戊烯-5-基)-n-(苯基)环丙烷-甲酰胺衍生物及相关化合物 |
| US7671221B2 (en) * | 2005-12-28 | 2010-03-02 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
| US7645789B2 (en) | 2006-04-07 | 2010-01-12 | Vertex Pharmaceuticals Incorporated | Indole derivatives as CFTR modulators |
| USRE50453E1 (en) | 2006-04-07 | 2025-06-10 | Vertex Pharmaceuticals Incorporated | Indole derivatives as CFTR modulators |
| IN2014KN02423A (cg-RX-API-DMAC7.html) | 2006-04-07 | 2015-05-01 | Vertex Pharma | |
| US10022352B2 (en) | 2006-04-07 | 2018-07-17 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
| US8563573B2 (en) | 2007-11-02 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as CFTR modulators |
| EP2164840A2 (en) | 2007-05-09 | 2010-03-24 | Vertex Pharmaceuticals Incorporated | Modulators of cftr |
| CN101827593B (zh) | 2007-08-24 | 2013-07-24 | 沃泰克斯药物股份有限公司 | 用于治疗(特别是)囊性纤维化的异噻唑并吡啶酮 |
| WO2009064959A1 (en) | 2007-11-16 | 2009-05-22 | Vertex Pharmaceuticals Incorporated | Isoquinoline modulators of atp-binding cassette transporters |
| US20100036130A1 (en) | 2007-12-07 | 2010-02-11 | Vertex Pharmaceuticals Incorporated | Processes for producing cycloalkylcarboxamido-pyridine benzoic acids |
| PL2639223T3 (pl) | 2007-12-07 | 2017-09-29 | Vertex Pharmaceuticals Incorporated | Sposób wytwarzania kwasów cykloalkilokarboksyamido-pirydyno-benzoesowych |
| PT2225230T (pt) * | 2007-12-07 | 2016-12-07 | Vertex Pharma | Formas sólidas de ácido 3-(6(1-(2,2-difluorobenzo[d][1,3] dioxol-5-il) ciclopropanocarboxamido)-3-metilpiridin-2-il) benzoico |
| EA201070699A1 (ru) * | 2007-12-07 | 2011-02-28 | Вертекс Фармасьютикалз Инкорпорейтед | Композиции 3-(6-(1-2,2-дифторбензо[d][1,3]диоксол-5-ил)циклопропанкарбоксамидо)-3-метилпиридин-2-ил)бензойной кислоты |
| NZ620944A (en) | 2008-02-28 | 2015-02-27 | Vertex Pharma | Heteroaryl derivatives as cftr modulators |
| EP2271621B1 (en) | 2008-03-31 | 2013-11-20 | Vertex Pharmaceuticals Incorporated | Pyridyl derivatives as cftr modulators |
| US12458635B2 (en) | 2008-08-13 | 2025-11-04 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
| US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
| AU2009296271A1 (en) * | 2008-09-29 | 2010-04-01 | Vertex Pharmaceuticals Incorporated | Dosage units of 3-(6-(1-(2,2-difluorobenzo [d] [1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
| NZ592685A (en) | 2008-10-23 | 2013-04-26 | Vertex Pharma | Modulators of cystic fibrosis transmembrane conductance regulator |
| JP5645834B2 (ja) * | 2008-10-23 | 2014-12-24 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | 嚢胞性線維症膜コンダクタンス制御因子の修飾因子 |
| HRP20181261T1 (hr) * | 2009-03-20 | 2018-12-14 | Vertex Pharmaceuticals Incorporated | Modulatori regulatora transmembranske provodljivosti cistične fibroze |
| SI2408750T1 (sl) | 2009-03-20 | 2015-11-30 | Vertex Pharmaceuticals Incorporated | Postopek za izdelavo modulatorjev cistično-fibroznega transmembranskega regulatorja prevodnosti |
| WO2011031745A1 (en) | 2009-09-09 | 2011-03-17 | Achaogen, Inc. | Antibacterial fluoroquinolone analogs |
| WO2011050215A1 (en) * | 2009-10-23 | 2011-04-28 | Vertex Pharmaceuticals Incorporated | Process for preparing modulators of cystic fibrosis transmembrane conductance regulator |
| US8802868B2 (en) | 2010-03-25 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide |
| EP2555754B1 (en) | 2010-04-07 | 2016-04-06 | Vertex Pharmaceuticals Incorporated | Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
| HRP20211752T1 (hr) | 2010-04-07 | 2022-02-18 | Vertex Pharmaceuticals Incorporated | Farmaceutski pripravci 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksamido)-3-metilpiridin-2-il)benzojeve kiseline i njihova primjena |
| KR20130056244A (ko) | 2010-04-22 | 2013-05-29 | 버텍스 파마슈티칼스 인코포레이티드 | 시클로알킬카르복스아미도-인돌 화합물의 제조 방법 |
| US8563593B2 (en) | 2010-06-08 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide |
| JP5525612B2 (ja) * | 2010-07-23 | 2014-06-18 | 国立大学法人 東京大学 | 含窒素複素環誘導体 |
| CN102816175B (zh) * | 2011-06-09 | 2015-12-16 | 上海汇伦生命科技有限公司 | 一种杂环并吡啶酮类化合物,其中间体、制备方法和用途 |
| LT2776427T (lt) | 2011-11-08 | 2017-04-10 | Vertex Pharmaceuticals Incorporated | Atp surišančios kasetės transporterių moduliatoriai |
| CN102643268B (zh) * | 2011-12-30 | 2014-05-21 | 沈阳药科大学 | 喹啉类及噌啉类化合物及其应用 |
| HK1203840A1 (en) | 2012-02-27 | 2015-11-06 | 沃泰克斯药物股份有限公司 | Pharmaceutical composition and administration thereof |
| US8674108B2 (en) | 2012-04-20 | 2014-03-18 | Vertex Pharmaceuticals Incorporated | Solid forms of N-[2,4-bis(1,1-dimethylethy)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| HK1209318A1 (en) | 2012-07-16 | 2016-04-01 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions of (r)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof |
| CN103694163A (zh) * | 2012-09-27 | 2014-04-02 | 上海先声药物研究有限公司 | 作为钾通道调节剂的化合物 |
| KR102280372B1 (ko) | 2013-11-12 | 2021-07-22 | 버텍스 파마슈티칼스 인코포레이티드 | Cftr 매개된 질환 치료용 약제학적 조성물의 제조 방법 |
| ES2885181T3 (es) | 2014-04-15 | 2021-12-13 | Vertex Pharma | Composiciones farmacéuticas para el tratamiento de enfermedades mediadas por el regulador de la conductancia transmembrana de fibrosis quística |
| JP6746569B2 (ja) | 2014-10-07 | 2020-08-26 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | 嚢胞性線維症膜貫通コンダクタンス制御因子のモジュレーターの共結晶 |
| DK3221692T3 (da) | 2014-11-18 | 2021-08-23 | Vertex Pharma | Fremgangsmåde til udførsel af tests med høj kapacitet ved hjælp af højtryksvæskekromatografi |
| WO2017168448A1 (en) | 2016-03-30 | 2017-10-05 | Council Of Scientific & Industrial Research | Silicon incorporated quinolines with anti-malarial and anti-toxoplasmosis activity |
| PL3615527T3 (pl) | 2017-06-30 | 2024-07-01 | Elanco Animal Health Gmbh | Nowe pochodne azachinoliny |
| WO2020158870A1 (ja) * | 2019-01-30 | 2020-08-06 | 学校法人慶應義塾 | パーキンソン病治療薬 |
| US11634349B2 (en) | 2020-03-17 | 2023-04-25 | Robert O. Hoffland | Two-stage biogas production system for anaerobic digesters |
| CR20230120A (es) | 2020-08-07 | 2023-09-01 | Vertex Pharma | Moduladores del regulador de la conductancia transmembrana de la fibrosis quística |
| US12324802B2 (en) | 2020-11-18 | 2025-06-10 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| WO2024072793A1 (en) * | 2022-09-26 | 2024-04-04 | Rectify Pharmaceuticals, Inc. | Pyridine carboxamide compounds and their use in treating medical conditions |
| WO2024072794A1 (en) * | 2022-09-26 | 2024-04-04 | Rectify Pharmaceuticals, Inc. | Pyridine carboxamide compounds and their use in treating medical conditions |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0366193A3 (en) | 1988-10-24 | 1992-01-08 | Norwich Eaton Pharmaceuticals, Inc. | Novel antimicrobial quinolonyl lactams |
| US5225418A (en) * | 1991-12-17 | 1993-07-06 | Du Pont Merck Pharmaceutical Company | 5H-(1,2)benzisothiazolo[2,3-a]quinoline-5-ones and analogs as antiinflammatory agents |
| DE69329856D1 (de) | 1992-05-20 | 2001-02-15 | Merck & Co Inc | Ester derivate von 4-aza-steroiden |
| DE69329240D1 (de) | 1992-05-20 | 2000-09-21 | Merck & Co Inc | 17-ether und thioether von 4-aza-steroiden |
| JPH11510156A (ja) | 1995-08-02 | 1999-09-07 | カイロサイエンス・リミテッド | キノロン類およびその医療上の使用 |
| DE19532235A1 (de) | 1995-08-31 | 1997-03-06 | Keppler Bernhard K Priv Doz Dr | An Phosphonsäuren gekoppelte antibakteriell wirksame Verbindungen zur Therapie von Infektionen im Bereich des Knochens |
| US7211045B2 (en) | 2002-07-22 | 2007-05-01 | Ep Medsystems, Inc. | Method and system for using ultrasound in cardiac diagnosis and therapy |
| US7138412B2 (en) | 2003-03-11 | 2006-11-21 | Bristol-Myers Squibb Company | Tetrahydroquinoline derivatives useful as serine protease inhibitors |
| US7939558B2 (en) * | 2004-06-04 | 2011-05-10 | The Regents Of The University Of California | Compounds having activity in increasing ion transport by mutant-CFTR and uses thereof |
| ME02799B (me) * | 2004-06-24 | 2018-01-20 | Vertex Pharma | Modulatori ATP-vezujućih kasetnih transportera |
| US7816406B2 (en) | 2004-09-17 | 2010-10-19 | Cylene Pharmaceuticals, Inc. | Quinolone analogs |
| CN101087609B (zh) | 2004-10-26 | 2012-11-14 | 詹森药业有限公司 | 因子Xa化合物 |
| GB0424959D0 (en) | 2004-11-11 | 2004-12-15 | Glaxo Group Ltd | Novel compounds |
| GB0424951D0 (en) | 2004-11-11 | 2004-12-15 | Glaxo Group Ltd | Novel compounds |
| WO2006076442A2 (en) | 2005-01-14 | 2006-07-20 | Janssen Pharmaceutica N.V. | Triazolopyrimidine derivatives |
| US7642270B2 (en) * | 2005-09-14 | 2010-01-05 | Janssen Pharmaceutica N.V. | 5-oxo-5,8-dihydro-pyrido-pyrimidine as inhibitors of c-fms kinase |
| CN101305000A (zh) | 2005-09-14 | 2008-11-12 | 詹森药业有限公司 | 作为c-fms激酶抑制剂的5-氧代-5,8-二氢-吡啶并-嘧啶类 |
| TW200800983A (en) | 2005-09-14 | 2008-01-01 | Janssen Pharmaceutica Nv | 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of C-FMS kinase |
| EP1979367A2 (en) * | 2005-12-24 | 2008-10-15 | Vertex Pharmaceuticals Incorporated | Quinolin-4-one derivatives as modulators of abc transporters |
| NZ581419A (en) * | 2007-05-25 | 2012-05-25 | Vertex Pharma | Modulators of cystic fibrosis transmembrane conductance regulator |
| CN101827593B (zh) * | 2007-08-24 | 2013-07-24 | 沃泰克斯药物股份有限公司 | 用于治疗(特别是)囊性纤维化的异噻唑并吡啶酮 |
-
2008
- 2008-09-15 CA CA2699382A patent/CA2699382C/en active Active
- 2008-09-15 WO PCT/US2008/076376 patent/WO2009036412A1/en not_active Ceased
- 2008-09-15 ES ES08830930.7T patent/ES2445442T3/es active Active
- 2008-09-15 NZ NZ583878A patent/NZ583878A/xx not_active IP Right Cessation
- 2008-09-15 EP EP08830930.7A patent/EP2201010B1/en active Active
- 2008-09-15 AU AU2008298545A patent/AU2008298545B2/en not_active Ceased
- 2008-09-15 CN CN200880111472.7A patent/CN101821266B/zh not_active Expired - Fee Related
- 2008-09-15 JP JP2010525061A patent/JP5461405B2/ja not_active Expired - Fee Related
-
2010
- 2010-03-12 US US12/722,642 patent/US8188283B2/en active Active
-
2012
- 2012-04-23 US US13/453,193 patent/US8410132B2/en active Active
-
2013
- 2013-02-27 US US13/778,949 patent/US8748612B2/en active Active